Improving the efficiency of the medicine provision system for patients with malignant neoplasms
Open Access
- 27 July 2022
- journal article
- research article
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 15 (2) , 209-220
Abstract
Background. One of the priorities of health care is the balance between the financial resources and the availability of effective medical care. The current approach of access to cancer medicines limits the timeliness and availability of treatment. At the same time, financial support from the government provides great costs on cancer drugs. However, these great costs are not rational.Objective: to assess the financing needs of the complete transfer of financial support of medical care in the field of oncology to the Compulsory Health Insurance (CHI) system by means of optimizing the functions of the day hospital.Material and methods. The achievement of the goal is planned to be reached by eliminating the unusual functions of oncological day hospital. We analyzed the regulatory legal documents regulating drug care and drug provision in the Russian Federation, data from depersonalized (anonymized) registers of the structure of hospitalizations in a day hospital for 2021. The methods of expert assessments, mathematical modeling, as well as literature data analysis were used. The study developed a model for assessing the need to finance the full transfer of medicine provision to the CHI system, including taking into account the hidden deficit.Results. The total amount of funds released from the reduction of irrational hospitalizations in day hospital conditions amounted to 2.08% of the funding level of the analyzed schemes. Taking into account the data of hospitalizations in oncological day hospital for 2021, the number of irrational hospitalizations in case of transfer of selected schemes to the outpatient stage will decrease by 16.1%. The transfer of all the medicine therapy to financing from the CHI funds will require significant additional budget expenditures in the amount of 62.5 billion rubles or 2.65% of the total costs of the State Guarantees Program for Provision of Free Medical Care to Citizens.Conclusion. Despite the rationality of the proposed changes in the field of improving access to medicine provision concerning cancer drugs and the identified justifications for changing the distribution of financial resources within the State Guarantees Program, there are difficulties. In order to solve this problem, a coordinated consideration of potential strategies to address the access to cancer medicines is needed.Keywords
This publication has 21 references indexed in Scilit:
- Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of LifeJournal of the National Comprehensive Cancer Network, 2019
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countriesThe Lancet, 2018
- Survival As a Quality Metric of Cancer Care: Use of the National Cancer Data Base to Assess Hospital PerformanceJournal of Oncology Practice, 2018
- The effect of structured education to patients receiving oral agents for cancer treatment on medication adherence and self-efficacyAsia-Pacific Journal of Oncology Nursing, 2017
- Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literaturePatient Preference and Adherence, 2016
- SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence) : Revised Publication Guidelines from a Detailed Consensus ProcessThe Permanente Journal, 2015
- Supporting the self-management of hypertension: Patients’ experiences of using a mobile phone-based systemJournal of Human Hypertension, 2015
- Cancer Survival: An Overview of Measures, Uses, and InterpretationJournal of the National Cancer Institute Monographs, 2014
- Projections of the Cost of Cancer Care in the United States: 2010-2020JNCI: Journal of the National Cancer Institute, 2011
- A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancerAnnals of Oncology, 2005